CLINICAL CHARACTERISTICS, ASSOCIATED FACTORS, AND TREATMENT OUTCOMES OF PSORIASIS WITH SECUKINUMAB AT CAN THO HOSPITAL OF DERMATO-VENEREOLOGY IN 2024
Main Article Content
Abstract
Background: Psoriasis is a systemic dermatologic and joint disease characterized by chronic progression, unpredictable flares, and frequent relapses. Clinical features of psoriasis are diverse, and its pathogenesis remains unclear, making treatment challenging. The development of biologic therapies, including secukinumab, has brought positive outcomes in the management of this disease. Objective: To describe the clinical characteristics, evaluate associated factors, and assess treatment outcomes of psoriasis patients treated with secukinumab at Can Tho hospital of DermatoVenereology in 2024. Materials and methods: A cross-sectional descriptive study was conducted on 30 adult patients with moderate-to-severe plaque psoriasis. Patients received subcutaneous secukinumab, and treatment efficacy was assessed using PASI, DLQI, and BSA scores at weeks 4, 8, and 12. Results: The 40-49 age group was predominant (40.0%), while most patients being male (70.0%). Pruritus was present in all patients (100%). Most patients had moderate psoriasis severity per PASI (93.3%) and severe disease per BSA (76.7%). At admission, quality of life was moderately affected in 70.0% of patients. Psychological stress was the most common trigger or exacerbating factor (56.7%). After 12 week treatment, PASI-75 increased from 50% at week 4 to 100% at week 12, and 66.7% of patients achieved the target treatment outcome per DLQI, with 83.3% classified as having mild psoriasis per BSA. The most common side effect was fatigue (13.3%). Conclusion: Pruritus was observed in all patients. Disease severity was predominantly moderate based on PASI and severe based on BSA scores. Psychological stress was a frequent trigger or aggravating factor. Secukinumab demonstrated excellent efficacy in treating psoriasis with minimal adverse effects.
Keywords
psoriasis, secukinumab, biologic therapies
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Gudjonsson J. E., Elder J. T.. Psoriasis. Fitzpatrick’s Dermatology 9th Edition. Mc Graw Hill; 2019. 457-497.
3. Brembilla Nicolo Costantino and Boehncke Wolf-Henning. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Frontiers in Immunology. 2023. 14, https://doi.org/10.3389/fimmu.2023.1186455.
4. Fala L. Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis. Am Health Drug Benefits. 2016. 9, 60-3.
5. Trần Nguyên Ánh Tú, Nguyễn Trọng Hào và Đặng Văn Em. Nghiên cứu thay đổi nồng độ IL17A và hs-CRP huyết thanh của bệnh nhân vảy nến thông thường điều trị bằng secukinumab. Journal of 108 - Clinical Medicine and Pharmacy. 2020.15(5).
6. Trương Thị Mộng Thường và Lê Ngọc Diệp. Chất lượng cuộc sống của bệnh nhân vảy nến điều trị tại Bệnh viện Da Liễu TP Hồ Chí Minh từ 01/09/2010 đến 30/04/2011. Tạp chí Y học Thành phố Hồ Chí Minh. 2011. 16(1), 47-51.
7. Từ Mậu Xương. Nghiên cứu đặc điểm lâm sàng, một số yếu tố liên quan và kết quả điều trị bệnh vảy nến thông thường bằng thuốc bôi Acid Salicylic tại Bệnh viện Da liễu Cần Thơ năm 2018-2020. Luận văn Bác sĩ Nội trú. Trường Đại học Y Dược Cần Thơ. 2020. 70.
8. Langley R. G., Elewski B. E., Lebwohl M., Reich K., Griffiths C. E. M., et al. Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials. New England Journal of Medicine. 2014. 371(4), 326-338, https://doi.org/10.1056/NEJMoa1314258.
9. Nguyen H. T., Pham N. T. U., Tran T. N. A., Nguyen N. T. T., Vu T. T. P. Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study. Dermatology and Therapy. 2021.11(5), 1613-1621, https://doi.org/10.1007/s13555-021-00581-1.
10. Foley P., Tsai T. F., Rodins K., Hamadah I. R., Ammoury A., et al. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study. Australas J Dermatol. 2022. 63(3), 312-320, https://doi.org/10.1111/ajd.13893.
11. Ding Y., Li W., Guan X., Liu N., Zhou Y., et al. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study. Clin Transl Sci. 2023. 16(10), 1803-1814, https://doi.org/10.1111/cts.13583.
12. Bissonnette R., Luger T., Thaçi D., Toth D., Lacombe A., et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018. 32(9), 1507-1514, https://doi.org/10.1111/jdv.14878.